JP Morgan Chase’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-26,969
| Closed | -$92K | – | 6108 |
|
|
2018
Q3 | $92K | Buy |
26,969
+3,176
| +13% | +$11.5K | ﹤0.01% | 4988 |
|
|
2018
Q2 | $89K | Buy |
23,793
+1,940
| +9% | +$9.45K | ﹤0.01% | 4883 |
|
|
2018
Q1 | $89K | Buy |
21,853
+84
| +0.4% | +$391 | ﹤0.01% | 4631 |
|
|
2017
Q4 | $101K | Buy |
21,769
+19,985
| +1,120% | +$110K | ﹤0.01% | 4667 |
|
|
2017
Q3 | $13K | Buy |
1,784
+232
| +15% | +$1.67K | ﹤0.01% | 4689 |
|
|
2017
Q2 | $11K | Buy |
1,552
+319
| +26% | +$1.99K | ﹤0.01% | 4651 |
|
|
2017
Q1 | $8K | Sell |
1,233
-198,462
| -99% | -$1.09M | ﹤0.01% | 4851 |
|
|
2016
Q4 | $1.17M | Buy |
199,695
+146,432
| +275% | +$800K | ﹤0.01% | 3357 |
|
|
2016
Q3 | $283K | Buy |
+53,263
| New | +$287K | ﹤0.01% | 3579 |
|
|
2016
Q1 | – | Sell |
-6,329
| Closed | -$32K | – | 5094 |
|
|
2015
Q4 | $32K | Sell |
6,329
-1,236,870
| -99% | -$5.88M | ﹤0.01% | 3998 |
|
|
2015
Q3 | $4.38M | Sell |
1,243,199
-552,252
| -31% | -$3.7M | ﹤0.01% | 2303 |
|
|
2015
Q2 | $17.9M | Sell |
1,795,451
-23,017
| -1% | -$247K | ﹤0.01% | 1478 |
|
|
2015
Q1 | $23.1M | Buy |
1,818,468
+168,016
| +10% | +$2.16M | 0.01% | 1336 |
|
|
2014
Q4 | $23.4M | Buy |
1,650,452
+558,248
| +51% | +$8.65M | 0.01% | 1372 |
|
|
2014
Q3 | $15M | Sell |
1,092,204
-16,002
| -1% | -$245K | ﹤0.01% | 1636 |
|
|
2014
Q2 | $17M | Sell |
1,108,206
-67,668
| -6% | -$959K | ﹤0.01% | 1438 |
|
|
2014
Q1 | $20M | Buy |
1,175,874
+26,921
| +2% | +$406K | 0.01% | 1314 |
|
|
2013
Q4 | $14.9M | Sell |
1,148,953
-1,825,948
| -61% | -$21.8M | ﹤0.01% | 1519 |
|
|
2013
Q3 | $30M | Buy |
2,974,901
+48,778
| +2% | +$434K | 0.01% | 1080 |
|
|
2013
Q2 | $21.9M | Buy |
+2,926,123
| New | +$22.9M | 0.01% | 1201 |
|
JP Morgan Chase's KERX Position: Q4 2018 in Review
JP Morgan Chase sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 26,969 shares — an estimated $92K sold.
JP Morgan Chase first reported a position in KERX in Q2 2013 and held it in 20 quarters. The position peaked at $30M in Q3 2013. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- JP Morgan Chase reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- JP Morgan Chase sold 26,969 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $92K.
- JP Morgan Chase first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 20 quarters.
- JP Morgan Chase's Keryx Biopharmaceuticals Inc position peaked at $30M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on JP Morgan Chase's 13F filing for Q4 2018, filed 11 Feb 2019.